Table 1.

Clinical and pathological characteristics of pCR and non-pCR patients in the test and training cohort

	Test cohort		p	Training cohort		p
	pCR	Non-pCR		pCR	Non-pCR
Amount	11	34		27	80
Age (years) mean ± SD, years	42.91 ± 10.26	50.09 ± 11.00	0.063	52.15 ± 9.42	48.70 ± 10.40	0.131
Clinical stage(%)
I	1 (9.1%)	0 (0.0%)	0.061	1 (3.7%)	0 (0.0%)	0.119
II	7 (63.6%)	14 (41.2%)		16 (59.3%)	39 (48.8%)
III	3 (27.3%)	20 (58.8%)		10 (37.0%)	41 (51.2%)
Histopathological subtype(%)
IDC	10 (90.9%)	30 (88.2%)	0.431	26 (96.3%)	69 (86.2%)	0.231
IDC + ILC/+IMPC/+Mucinous cancer	1 (9.1%)	1 (3.0%)		0((0.0%)	8 (10%)
ILC/IMPC/Mucinous cancer	0 (0.0%)	3 (8.8%)		1 (3.7%)	3 (3.8%)
Molecular subtype(%)
Luminal A	2 (18.1%)	6 (17.6%)	0.423	3 (11.1%)	18 (22.5%)	0.309
Luminal B	3 (27.3%)	11 (32.4%)		9 (33.3%)	33 (41.3%)
Triple negative	4 (36.4%)	5 (14.7%)		4 (14.8%)	9 (11.2%)
HER2 overexpression	2 (18.1%)	12 (35.3%)		11 (40.7%)	20 (25%)
ER status(%)
Positive	6 (54.5%)	17 (50.0%)	0.793	12 (44.4%)	51 (63.7%)	0.078
Negative	5 (45.5%)	17 (50.0%)		15 (55.6%)	29 (36.3%)
PR status(%)
Positive	6 (54.5%)	16 (47.1%)	0.666	11 (40.7%)	41 (51.3%)	0.345
Negative	5 (45.5%)	18 (52.9%)		16 (59.3%)	39 (48.7%)
HER2 status(%)
Positive	7 (63.6%)	20 (58.8%)	0.777	15 (55.6%)	39 (48.7%)	0.541
Negative	4 (36.4%)	14 (41.2%)		12 (44.4%)	41 (51.3%)
Ki67(%)
High	3 (27.3%)	21 (61.8%)	0.046a	11 (40.7%)	52 (65%)	0.027a
Low	8 (72.7%)	13 (38.2%)		16 (59.3%)	28 (35%)

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2;IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IMPC, invasive micropapillary carcinoma; PR, progesterone receptor.

^ap‹0.05